Cargando…
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers
Estrogen receptor-α positive (ERα+) breast cancer accounts for approximately 70–80% of the nearly 25,0000 new cases of breast cancer diagnosed in the US each year. Endocrine-targeted therapies (those that block ERα activity) serve as the first line of treatment in most cases. Despite the proven bene...
Autores principales: | Williams, Michelle M., Lee, Linus, Werfel, Thomas, Joly, Meghan M. Morrison, Hicks, Donna J., Rahman, Bushra, Elion, David, McKernan, Courtney, Sanchez, Violeta, Estrada, Monica V., Massarweh, Suleiman, Elledge, Richard, Duvall, Craig, Cook, Rebecca S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833697/ https://www.ncbi.nlm.nih.gov/pubmed/29343814 http://dx.doi.org/10.1038/s41419-017-0072-x |
Ejemplares similares
-
Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth
por: Morrison, Meghan M., et al.
Publicado: (2015) -
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
por: Williams, Michelle M., et al.
Publicado: (2019) -
ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation
por: Williams, Michelle M., et al.
Publicado: (2017) -
Estrogen response in luminal breast cancer
por: Rangel, Leticia B. A., et al.
Publicado: (2013) -
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
por: Hashmi, Atif Ali, et al.
Publicado: (2018)